Recombinant Ranibizumab Biosimilar 抗体
This Humanized 单克隆 anti-not_set antibody specifically detects not_set in FACS 和 in vivo. The antibody is reactive with 人 samples.
产品编号 ABIN7200657
发货至:
中国
Contact our Customer Service for availability and price in your country.
Contact Info
Our Local Distributor
中国
北京 101111
北京 101111
No. 88 KeChuang 6th Street
Beijing Economic Technological Development Area
Room 801-803
Quick Overview for Recombinant Ranibizumab Biosimilar 抗体 (ABIN7200657)
抗原
Ranibizumab Biosimilar
抗体类型
Recombinant Antibody
片段
Fab fragment
适用
人
宿主
Humanized
克隆类型
单克隆
应用范围
Flow Cytometry (FACS), In vivo Studies (in vivo)
质量等级
Research Grade
-
-
原理
- Ranibizumab Biosimilar, Human VEGF Monoclonal Antibody Fragment (Fab)
-
特异性
- The Fab protein ranibizumab specifically binds to the human VEGF-A.
-
产品特性
- The humanized anti-VEGF-A monoclonal antibody drug Bevacizumab (trade name Avastin, Genentech/Roche) is the first clinically available angiogenesis inhibitor in the United States. The humanized anti-VEGF-A monoclonal antibody fragment (Fab) Ranibizumab (trade name Lucentis, Genentech) is derived from the same parent mouse antibody as bevacizumab. Both antibody drugs produce angiogenesis inhibition and slow the growth of new blood vessels. Ranibizumab is much smaller than the parent complete antibody but shows stronger binding to VEGF-A after affinity maturation. Ranibizumab can also be used to treat the "wet" type of age-related macular degeneration (AMD, also ARMD), a common form of age-related vision loss. Vascular endothelial growth factor A (VEGF-A) stimulates angiogenesis in a variety of cancers, including colorectal, lung, breast, glioblastoma, kidney, and ovarian cancers.
-
纯化方法
- Protein A or G affinity column
-
纯度
- >95 % by reducing SDS-PAGE
-
过滤
- 0.2 μm filtered
-
内毒素水平
- < 1 EU per 1 mg of the protein by the LAL method
-
免疫原
- The research grade Fab protein ranibizumab was produced in the ranibizumab biosimilar E.coli cell line.
-
亚型
- IgG1
-
-
-
应用备注
- Functional assay, neutralization.
-
限制
- 仅限研究用
-
-
-
状态
- Liquid
-
浓度
- > 3 mg/mL
-
缓冲液
- PBS, pH 7.4, no stabilizers or preservatives.
-
储存液
- Without preservative
-
储存条件
- 4°C,-20 °C
-
储存方法
- 12 months from date of receipt, -20 to -70°C as supplied. 1 month from date of receipt, 2 to 8°C as supplied.
-
有效期
- 12 months
-
-
- Ranibizumab Biosimilar
-
物质类
- Biosimilar
抗原
-
You are here:
